Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
Unlike traditional invasive procedures, Quantum RF is an aspiration-free, non-surgical treatment, making it an ideal choice for those seeking effective body contouring with minimal discomfort and no downtime
Values are provided as published reference figures for research identification
doi: 10.3390/ijms25179351 44 KrisanapanPSanpawithayakulKPattharanitimaPThongprayoonCMiaoJMaoMAet al
Browse by category in Research Peptides, or use popular product pages like Retatrutide, Tirzepatide, BPC-157, NAD+, GHK-Cu and MOTS-c
Singh S, Chandan S, Dahiya DS, et al
